San Diego-based Ambit Biosciences, the developer of biopharmaceuticals for the treatment of cancer, inflammatory disease and other conditions, said this morning that it has named a Chief Medical Officer. The company said it has appointed Athena Countouriotis, M.D., to head up development of its lead compound, quizartinib (AC220), which is targeted at treating acute myeloid leukemia (AML). Countouriotis was previously at Pfizer, and also has served at Bristol-Myers Squibb and Cell Therapeutics.
Top NewsWednesday, February 8, 2012
Ambit Biosciences Names Chief Medical Officer